Morgan Stanley Raises Vir Biotechnology Target Price to $15

Wednesday, 5 June 2024, 16:14

The latest report from Morgan Stanley reveals an increased target price for Vir Biotechnology to $15, up from $12. This upgrade reflects the firm's positive outlook on the company's performance and potential market growth. Investors may find this development noteworthy as it suggests increasing value in Vir Biotechnology shares, potentially impacting their investment decisions.
https://store.livarava.com/e64b7d4f-2370-11ef-a40d-9d5fa15a64d8.jpg
Morgan Stanley Raises Vir Biotechnology Target Price to $15

Morgan Stanley Boosts Vir Biotechnology Target Price

The latest report from Morgan Stanley has raised Vir Biotechnology's target price to $15 from $12. This upgrade signifies a positive outlook on the company's performance and market potential.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe